Strados Labs Remote Wearable in BI IPF Trial
Research has suggested that cough may be associated with worse outcomes in pulmonary fibrosis. Boehringer Ingelheim will assess how monitoring cough and crackles with the RESP Biosensor can be used to monitor the status of patients with this disease.
Boehringer Ingelheim will remotely monitor patients using Strados Labs’ FDA-cleared pulmonary wearable device in an upcoming idiopathic pulmonary fibrosis (IPF) pilot study. The Strados RESP Biosensor will be used to monitor cough frequency, severity, and type along with wheezing and other abnormal sounds, such as crackles, IPF patients at home.
Read more about the study.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
